SARS-CoV-2 Blocking Antibodies

Receptor binding is the first step in viral infection. For coronaviruses, a cell-surface Spike (S) protein mediates their entry into host cells. The S protein on SARS-CoV-2 recognizes and binds to ACE-2 through its receptor binding domain (RBD). Thus, these proteins could be viable therapeutic targets. Blocking the interaction between ACE-2 and the S protein, for example with antibodies directed against either ACE-2 or the S Protein RBD, could, in theory, prevent SARS-CoV-2 infection. Other factors that facilitate cell-virus interactions or cell entry, such as Neuropilin-1, are also being investigated as potential antiviral therapeutics. R&D Systems offers blocking antibodies for many of these factors that are ideal for use in blocking assays.